POSC49 The Cost-Effectiveness of Brentuximab Vedotin in Frontline Systemic Anaplastic Large Cell Lymphoma in France
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.454
https://www.valueinhealthjournal.com/article/S1098-3015(21)02249-X/fulltext
Title :
POSC49 The Cost-Effectiveness of Brentuximab Vedotin in Frontline Systemic Anaplastic Large Cell Lymphoma in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02249-X&doi=10.1016/j.jval.2021.11.454
First page :
Section Title :
Open access? :
No
Section Order :
11226